Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: The Freiburg experience (1989-2002)

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 12

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Colorectal Cancer

World J Gastroenterol. Mar 28, 2006; 12(12): 1849-1858
Published online Mar 28, 2006. doi: 10.3748/wjg.v12.i12.1849

Table 1 Patient characteristics

	Adjuvant radiochemotherapy n (%)	Neoadjuvant radiochemotherapy n (%)	All n (%)
Gender
Female	148 (63.5)	38 (71.7)	186 (65.0)
Male	85 (36.5)	15 (28.3)	100 (35.0)
Age
≤Median age of 62 yr	134 (57.5)	32 (60.4)	166 (58.0)
> Median age of 62 yr	99 (42.5)	21 (39.6)	120 (42.0)
Tumor location
Upper third	35 (15.1)	0 (0.0)	35 (12.2)
Middle third	100 (42.9)	23 (43.4)	123 (43.0)
Lower third	87 (37.3)	25 (47.2)	112 (39.2)
Not known	11 (4.7)	5 (9.4)	16 (5.6)
Surgical Resection
Anterior (LAR)	133 (56.8)	13 (24.6)	146 (51.0)
Abdominoperineal (APR)	100 (43.2)	40 (75.4)	140 (49.0)
R status
R0	197 (84.5)	37 (69.8)	234 (81.8)
R1	17 (7.3)	5 (9.4)	22 (7.7)
R2	4 (1.8)	2 (3.8)	6 (2.1)
not known	15 (6.4)	9 (17.0)	24 (8.4)
Stage
II	75 (32.2)	17 (32.1)	92 (32.2)
III	158 (67.8)	36 (67.9)	194 (67.8)
N stage
N0	74 (31.8)	17 (32.1)	91 (31.8)
N1	81 (34.8)	27 (50.9)	108 (37.8)
N2	78 (33.4)	9 (17.0)	87 (30.4)
Grading
G I	11 (4.7)	9 (17.0)	20 (7.0)
G II	161 (69.1)	29 (54.7)	190 (66.5)
G III	44 (18.9)	9 (17.0)	53 (18.5)
Not known	17 (7.3)	6 (11.3)	23 (8.0)
CEA
< 3 ng/mL	102 (43.8)	16 (30.2)	118 (41.3)
≥ 3 ng/mL	102 (43.8)	16 (30.2)	118 (41.3)
Not known	29 (12.4)	21 (39.6)	50 (17.4)
RTOG
RTOG 0	96 (41.2)	30 (56.6)	126 (44.1)
RTOG I	75 (32.2)	14 (26.4)	89 (31.1)
RTOG II	46 (19.7)	9 (17.0)	55 (19.2)
RTOG III	13 (5.6)	0 (0.0)	13 (4.6)
RTOG IV	3 (1.3)	0 (0.0)	3 (1.0)
RTOG V	0 (0.0)	0 (0.0)	0 (0.0)

Citation: Weissenberger C, Geissler M, Otto F, Barke A, Henne K, Plehn GV, Rein A, Müller C, Bartelt S, Henke M. Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: The Freiburg experience (1989-2002). World J Gastroenterol 2006; 12(12): 1849-1858
URL: https://www.wjgnet.com/1007-9327/full/v12/i12/1849.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i12.1849

Weissenberger C, Geissler M, Otto F, Barke A, Henne K, Plehn GV, Rein A, Müller C, Bartelt S, Henke M. Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: The Freiburg experience (1989-2002). World J Gastroenterol 2006; 12(12): 1849-1858 [PMID: 16609990 DOI: 10.3748/wjg.v12.i12.1849]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.